Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Randox Laboratories Ltd.

Latest From Durata Therapeutics Inc.

AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed

Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.

Business Strategies Infectious Diseases

Iterum Therapeutics Focused On First Oral Penem

Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.

StartUps and SMEs Financing

Medicare Add-On Payments For Praxbind, Andexanet Under Consideration

Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.

BioPharmaceutical United States

With $36B From Teva, What Should Allergan Buy Next?

Allergan has the cash on hand for another transformational transaction, having sold its generics business just three years since Watson’s purchase of Actavis created a generics powerhouse and just months after the purchase of Allergan brought in a brand platform and new name.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Randox Laboratories Ltd.
  • Senior Management
  • Peter FitzGerald, MD, Managing Dir.
  • Contact Info
  • Randox Laboratories Ltd.
    Phone: (44) 28 9442 2413
    55 Diamond Rd.
    Crumlin, BT29 4QY